Vaxcyte Phase 3 positive reshapes pneumococcal vaccine field

Vaccine developer Vaxcyte reported today that candidate vaccine VAX-31 met all primary endpoints in the OPUS-1 adult Phase 3 trial, sending shares up 91% premarket; we focus on the pneumococcal vaccine shift. Higher approval odds directly re-rate its equity value; market focus is on Vaxcyte alone and has not fully priced fill-finish partner Thermo Fisher. If commercialization scales, Thermo Fisher's fill-finish orders may materialize; if approval or commercialization stalls, Pfizer and Merck keep their adult PCV share. We track filing acceptance and later pivotal data; a primary-endpoint miss would reverse this read.

Event Impact Map

The map has 3 path segments around the VAX-31 adult Phase 3 readout: a direct re-rating of Vaxcyte equity, transmission to Thermo Fisher's fill-finish take-up via commercial scale-up, and incumbent share kept by Pfizer and Merck in the downside case.

Vaccine approval value re-rating

Direct benefit

Vaxcyte develops and commercializes VAX-31; the Phase 3 hit directly re-rates its equity value.

PCVXVaxcyte, Inc.

Fill-finish capacity take-up

Extended diffusion

Thermo Fisher takes up Vaxcyte's U.S. fill-finish manufacturing, worth up to $1 billion.

TMOThermo Fisher Scientific, Inc.

Incumbent share take-up

Hedge

Pfizer and Merck are incumbent adult PCV makers; they keep share if VAX-31 fails.

MRKMerck & Co., Inc.PFEPfizer Inc.

Capital Flow: Opportunities & Hedging

Nome	Último preço	Variação	Tendência	Justificação	Ação
PCVX Vaxcyte, Inc.	--	--	--	Vaccine developer Vaxcyte owns VAX-31; the Phase 3 hit lifts approval and commercialization odds, with a 91% premarket gain pricing in an initial re-rating. Track filing acceptance and later pivotal data; a primary-endpoint miss would weaken the case.	Negociar

--

--

Vaccine developer Vaxcyte owns VAX-31; the Phase 3 hit lifts approval and commercialization odds, with a 91% premarket gain pricing in an initial re-rating. Track filing acceptance and later pivotal data; a primary-endpoint miss would weaken the case.

AI Picks History

Tracks the 7-day high following AI selection.

Applied Digital Corporation

+5.83%

Data de seleção2026/10/04

Fecho anterior$25,37

Máximo de 7 dias$26,85

Applied Digital Corporation

+5.83%

Data de seleção2026/10/03

Fecho anterior$25,37

Máximo de 7 dias$26,85

Hewlett Packard Enterprise Company

+8.81%

Data de seleção2026/10/02

Fecho anterior$64,59

Máximo de 7 dias$70,28

ASE Technology Holding Co., Ltd.

+7.59%

Data de seleção2026/10/01

Fecho anterior$44,54

Máximo de 7 dias$47,92

Carnival Corporation Ltd.

+228.25%

Data de seleção2026/09/30

Fecho anterior$25,13

Máximo de 7 dias$82,49

Applied Materials Inc

+12.44%

Data de seleção2026/09/29

Fecho anterior$486,71

Máximo de 7 dias$547,25

Applied Materials Inc

+14.04%

Data de seleção2026/09/28

Fecho anterior$479,87

Máximo de 7 dias$547,25

Viavi Solutions Inc.

+18.95%

Data de seleção2026/09/27

Fecho anterior$40,69

Máximo de 7 dias$48,40

Generated from public information · AI-assisted research only · Not investment advice · DYOR

Vaxcyte Phase 3 positive reshapes pneumococcal vaccine field

Vaccine developer Vaxcyte reported today that candidate vaccine VAX-31 met all primary endpoints in the OPUS-1 adult Phase 3 trial, sending shares up 91% premarket; we focus on the pneumococcal vaccine shift. Higher approval odds directly re-rate its equity value; market focus is on Vaxcyte alone and has not fully priced fill-finish partner Thermo Fisher. If commercialization scales, Thermo Fisher's fill-finish orders may materialize; if approval or commercialization stalls, Pfizer and Merck keep their adult PCV share. We track filing acceptance and later pivotal data; a primary-endpoint miss would reverse this read.

Event Impact Map

The map has 3 path segments around the VAX-31 adult Phase 3 readout: a direct re-rating of Vaxcyte equity, transmission to Thermo Fisher's fill-finish take-up via commercial scale-up, and incumbent share kept by Pfizer and Merck in the downside case.

Vaccine approval value re-rating

Direct benefit

Vaxcyte develops and commercializes VAX-31; the Phase 3 hit directly re-rates its equity value.

PCVXVaxcyte, Inc.

Fill-finish capacity take-up

Extended diffusion

Thermo Fisher takes up Vaxcyte's U.S. fill-finish manufacturing, worth up to $1 billion.

TMOThermo Fisher Scientific, Inc.

Incumbent share take-up

Hedge

Pfizer and Merck are incumbent adult PCV makers; they keep share if VAX-31 fails.

MRKMerck & Co., Inc.PFEPfizer Inc.

Capital Flow: Opportunities & Hedging

Nome	Último preço	Variação	Tendência	Justificação	Ação
PCVX Vaxcyte, Inc.	--	--	--	Vaccine developer Vaxcyte owns VAX-31; the Phase 3 hit lifts approval and commercialization odds, with a 91% premarket gain pricing in an initial re-rating. Track filing acceptance and later pivotal data; a primary-endpoint miss would weaken the case.	Negociar

--

--

Vaccine developer Vaxcyte owns VAX-31; the Phase 3 hit lifts approval and commercialization odds, with a 91% premarket gain pricing in an initial re-rating. Track filing acceptance and later pivotal data; a primary-endpoint miss would weaken the case.

AI Picks History

Tracks the 7-day high following AI selection.

APLDApplied Digital Corporation

$25,37 → $26,85

Selecionado 2026/10/04

APLDApplied Digital Corporation

$25,37 → $26,85

Selecionado 2026/10/03

HPEHewlett Packard Enterprise Company

$64,59 → $70,28

Selecionado 2026/10/02

ASXASE Technology Holding Co., Ltd.

$44,54 → $47,92

Selecionado 2026/10/01

CCLCarnival Corporation Ltd.

$25,13 → $82,49

Selecionado 2026/09/30

AMATApplied Materials Inc

$486,71 → $547,25

Selecionado 2026/09/29

AMATApplied Materials Inc

$479,87 → $547,25

Selecionado 2026/09/28

VIAVViavi Solutions Inc.

$40,69 → $48,40

Selecionado 2026/09/27

Generated from public information · AI-assisted research only · Not investment advice · DYOR